NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

How many times did I mention hemisphere here over the years with all the hand waving.


>>The DCVax-L trial was limited to patients with tumors in one hemisphere,

>>Patients with progression at the completion of radiotherapy were excluded. These are high level inclusion criteria, aiming at enrolling a select group of patients with very favorable clinical characteristics assumed necessary to show efficacy of the vaccine strategy—but also likely to be associated with improved OS.

>>These data show the huge impact of residual enhancement at the time of progression, which is also present in the DCVax-L trial resulting in a 3 months difference in OS between minimal and significant residual disease using a similar definition

>>of the 5 newly diagnosed glioblastoma trials used for comparison no attempt was made to control for residual tumor volume.